http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2022153746-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f4facd06daf8853cc7075ae9e2bd2c5c |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-06 |
| filingDate | 2021-11-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ed069b4a010a4fcb8d8efcde4da9dd7d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e2c048437e46e33e77642cf4aecbb52a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f5ea894b13b51369c2885687e5e80cbb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_49485bc769d74d1cfc7c5fd9cac4afbd http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fd8e62007dbc0c282e853ad9c844d2a7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_81af82f67b78afa5b72b1cb927012e89 |
| publicationDate | 2022-05-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2022153746-A1 |
| titleOfInvention | Nitrogen oxide-donating pde-5 and/or pde-6 inhibitor compounds, and uses thereof |
| abstract | The present disclosure provides uses of phosphodiesterase 5 (PDE-5) and/or phosphodiesterase 6 (PDE-6) inhibitor compounds and uses of compositions including said compounds. In some embodiments, said compounds are nitrogen oxide (NO) donating PDE-5 and/or -6 inhibitor compounds that include a nitrogen oxide-containing donor substituent attached to a benzenesulfonamide group. The compounds can provide dual functionality for increasing protein kinase G (PKG) activity by inhibiting PDE-5 and PDE-6, and/or stimulating guanylate cyclase via donation of NO from the donor substituent of the compound. The present disclosure also provides methods of using said compounds and compositions for inhibiting PDE-5 and/or -6 and increasing activity of PKG. The compounds and compositions find use in the treatment of a variety of eye diseases. For example, the subject compounds may be used as a therapeutic agent for glaucoma, age-related macular degeneration, diabetic retinopathy, xerophthalmia, dry eye syndrome, cataracts or uveitis. |
| priorityDate | 2020-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 830.